MedPath

Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease

Not Applicable
Withdrawn
Conditions
Alzheimer Disease
Interventions
Device: TMS-Sham with MindMotion Go
Device: TMS-Stimulation with MindMotion Go
Device: TMS stimulation with X-Torp task
Device: TMS-Sham with X-Torp task
Registration Number
NCT04440891
Lead Sponsor
Ali Rezai
Brief Summary

This is a randomized sham control study to evaluate how repetitive Transcranial Magnetic Stimulation (rTMS), interactive cognitive training, or the combination of rTMS and cognitive training reduce the cognitive decline of patients diagnosed with Alzheimer's disease

Detailed Description

Participants may be assigned to one of four experimental arms (1-TMS-Stimulation with X-Torp task, 2-TMS-Stimulation with MindMotion Go, 3-TMS-Sham with X-Torp task, 4-TMS-Sham with MindMotion Go.) The study will be conducted in two phases. During Phase 1, participants will be randomized between experimental conditions 1 and 4. Data will be analyzed upon completion of Phase1 and Phase 2 will commence only if there is efficacy in the TMS arm. During Phase2, participants will be randomized to arms 2 and 3.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Male or Female between 50-85 years of age

  • Able and willing to give informed consent
  • Probable AD consistent with NIA/AA criteria
  • Modified Hachinski Ischemia Scale (MHIS) score of <= 4
  • Geriatric Depression Scale (GDS) score of <= 6
  • Mini Mental State Exam (MMSE) score 18-26. The MMSE adjusted scoring instructions may be followed for screening patients as applicable.
Exclusion Criteria
  • Unstable medical conditions
  • Visual impairments
  • Mobility limitations
  • Cognition-enhancing medication unless on a stable dosage for at least 3 months before the start of the trial.
  • History of epilepsy or seizure disorder
  • History of psychosis
  • Current thoughts of suicidal ideation or self-harm as assessed by the Columbia-Suicide severity rating scale score
  • Progressive neurological disorder or focal signs of abnormality on neurological exam as conducted by a neurologist (other than current diagnosis of AD)
  • Tinnitus
  • Metal implants (excluding dental fillings)
  • Possible pregnancy
  • Substance use disorder within the past six months
  • Have other mental or physical conditions that are inappropriate for study participation at PI's or delegated sub investigator's discretion.
  • Intake of one or a combination of the drugs that may due to their significant seizure threshold lowering potential

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TMS-Sham with MindMotion GoTMS-Sham with MindMotion GoTMS sham control with sham VR 2
TMS-Stimulation with MindMotion GoTMS-Stimulation with MindMotion GoTMS with VR 2 experimental arm
TMS-Stimulation with X-Torp taskTMS stimulation with X-Torp taskTMS with VR 1 experimental arm
TMS-Sham with X-Torp taskTMS-Sham with X-Torp taskTMS sham control with VR 1
Primary Outcome Measures
NameTimeMethod
Cognitive Performance6 months after completion study procedure

Change in cognitive task performance over time using the total score on the Mini Mental State Examination (range 0-30)

Secondary Outcome Measures
NameTimeMethod
Brain MRI6 months after completion of study procedure compared to screening

Change in brain structure and function over time

Memory Performance6 months after completion of study procedure compared to screening

Total recall on the California Verbal Learning Test - short form (range 0-36)

Trial Locations

Locations (1)

West Virginia University Rockefeller Neuroscience Institute

🇺🇸

Morgantown, West Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath